IMMUNIC INC (IMUX:NASDAQ)
$1.22 0.05 (4.2735%)
Analysed IMMUNIC INC (IMUX:NASDAQ) News Sources
Immunic to Participate in Scientific and Medical Conferences in April
09-04-2026
yahoo.com
Immunic COO highlights the importance of science-led innovation to mark World Health Day
07-04-2026
yahoo.com
Immunic Regains Compliance with Nasdaq Minimum Bid Price Requirement
01-04-2026
yahoo.com
Immunic appoints biopharmaceutical executive Jon Congleton to board
31-03-2026
proactiveinvestors.com
Immunic Strengthens Its Board of Directors with the Appointment of Seasoned Biopharmaceutical Executive Jon Congleton
31-03-2026
yahoo.com
Stock Market Today, March 24: Oil, AI, and Private Credit Fears Weigh on Markets
24-03-2026
fool.com
Immunic, Inc. (IMUX) Announces European Patent Grant for Vidofludimus Calcium
20-03-2026
yahoo.com
Immunic Conference: “Transformative” 2026 Ahead With Pivotal MS Data Due Late Year, NDA Next
20-03-2026
marketbeat.com
Immunic Details Vidofludimus Calcium MS Strategy, Phase III Timeline at Leerink Conference
18-03-2026
marketbeat.com
Immunic secures European patent for MS drug candidate vidofludimus calcium
10-03-2026
proactiveinvestors.com
What is the current price of IMMUNIC INC (IMUX:NASDAQ)?
The current price of IMMUNIC INC (IMUX:NASDAQ) is $1.22.
IMMUNIC INC (IMUX:NASDAQ) absolute price change since previous trading day?
The absolute price change of IMMUNIC INC (IMUX:NASDAQ) since the previous trading day is $0.05.
IMMUNIC INC (IMUX:NASDAQ) percentage price change since previous trading day?
The percentage price change of IMMUNIC INC (IMUX:NASDAQ) since the previous trading day is 4.2735%.
What is the most recent average sentiment score for IMMUNIC INC (IMUX:NASDAQ)?
The most recent average sentiment score for IMMUNIC INC (IMUX:NASDAQ) is 72 out of 100.
What is the most recent average sentiment for IMMUNIC INC (IMUX:NASDAQ)?
The most recent sentiment for IMMUNIC INC (IMUX:NASDAQ) is .
SEC-8K** Filing Available For IMMUNIC INC (IMUX:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.